UPDATE: AxoGen (AXGN) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/30/2026
- US stock futures rise as Microsoft offsets Fed concerns
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner seeks new funds after rout - report
- US 30-year yield hits 2007 high, stocks attempt post-earnings recovery
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Wall Street closes down sharply after Fed holds rates unchanged
- How will the S&P 500 react to today’s FOMC? JPM lays out the playbook
- Grant Thornton Advisors to buy CBIZ in $5 billion deal, expand US accounting reach
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
AxoGen, Inc. Reports 2018 First Quarter Financial Results
April 30, 2018 4:05 PM EDTALACHUA, Fla., April 30, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today reported financial results and business highlights for the first quarter ended March 31, 2018.
First Quarter 2018 Financial Results and Recent Business Highlights
Revenue of $17.3 million, up 41% compared to $12.2 million in the first quarter of 2017Gross margin of 84.3% compared to 84.4% in the first quarter of 2017Net loss for the quarter was $5.6 million, or $0.16 per share, compared to net loss... More